Cargando…

New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison

BACKGROUND: In the US, the prevalence of hepatitis C virus (HCV) has surpassed the prevalence of human immunodeficiency virus (HIV), with about 3.3 million people chronically infected with the disease. Given the aging of the Baby Boomer generation and the subsequent implementation of age-based scree...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poonsapaya, Jennifer M., Einodshofer, Michael, Kirkham, Heather S., Glover, Pheophilus, DuChane, Janeen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595188/ https://www.ncbi.nlm.nih.gov/pubmed/26445564 http://dx.doi.org/10.1186/s12962-015-0043-y

Ejemplares similares

Evaluation of Increased Adherence and Cost Savings of an Employer Value-Based Benefits Program Targeting Generic Antihyperlipidemic and Antidiabetic Medications
por: Clark, Bobby, et al.
Publicado: (2014)

mer-Trichloridotris(tetrahydrothiophene-κS)iridium(III): preparation and comparison with other mer-trichloridotris(tetrahydrothiophene-κS)metal complexes
por: Brown, Loren C., et al.
Publicado: (2016)

Crystal structures of (η(4)-cycloocta-1,5-diene)bis(1,3-dimethylimidazol-2-ylidene)iridium(I) iodide and (η(4)-cycloocta-1,5-diene)bis(1,3-diethylimidazol-2-ylidene)iridium(I) iodide
por: Bernier, Chad M., et al.
Publicado: (2020)

Cost-effectiveness analysis of an outreach model of Hepatitis C Virus (HCV) assessment to facilitate HCV treatment in primary care
por: Brain, David, et al.
Publicado: (2020)

Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China
por: Chen, Hai, et al.
Publicado: (2017)

All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice: Madrid coinfection registry findings
por: Berenguer, Juan, et al.
Publicado: (2018)

Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States
por: Razavi, Homie, et al.
Publicado: (2013)

Noble Metal Organometallic Complexes Display Antiviral Activity against SARS-CoV-2
por: Chuong, Christina, et al.
Publicado: (2021)

Association between hepatitis C virus and oral lichen planus: HCV and oral Lichen Planus
por: Oliveira Alves, Mônica Ghislaine, et al.
Publicado: (2011)

Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies
por: Krauth, Christian, et al.
Publicado: (2019)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
por: Janardhan, Sujit V, et al.
Publicado: (2015)

Estimated Cost and Savings in a Patient Management Program for Oral Oncology Medications: Impact of a Split-Fill Component
por: Staskon, Francis C., et al.
Publicado: (2019)

Hepatitis C (HCV) therapy for HCV mono-infected and HIV-HCV co-infected individuals living in Nepal
por: KC, Sudhamshu, et al.
Publicado: (2020)

Hepatitis C Virus (HCV) Infection and Hepatic Steatosis
por: Yoon, Eugene J., et al.
Publicado: (2006)

Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis
por: Rao, Huiying, et al.
Publicado: (2020)

Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence
por: Cipriano, Lauren E., et al.
Publicado: (2018)

Oral lichen planus and HCV infection
por: Tenório, Jefferson R., et al.
Publicado: (2020)

Hepatitis C virus (HCV) infection and re-infection among HCV- and HIV/HCV-infected injection drug users
por: Conway, B, et al.
Publicado: (2010)

GP73 Is Upregulated by Hepatitis C Virus (HCV) Infection and Enhances HCV Secretion
por: Hu, Longbo, et al.
Publicado: (2014)

Hepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral Genotypes
por: Mancini, Nicasio, et al.
Publicado: (2009)

Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysis
por: Sadeghimehr, Maryam, et al.
Publicado: (2021)

Epidemiology of Hepatitis C Virus (HCV) Infection
por: Sy, Theodore, et al.
Publicado: (2006)

Transcriptional responses define dysregulated immune activation in Hepatitis C (HCV)-naïve recipients of HCV-infected donor kidneys
por: Steinbrink, Julie M., et al.
Publicado: (2023)

Investigating pathogenic SNP of PKCι in HCV-induced hepatocellular carcinoma
por: Khan, Naila, et al.
Publicado: (2023)

Assessment of total hepatitis C virus (HCV) core protein in HCV-related mixed cryoglobulinemia
por: Russi, Sabino, et al.
Publicado: (2014)

Analysis of hepatitis non-treatment causes in a cohort of HCV and HCV/HIV infected patients
por: Pereira, Karen, et al.
Publicado: (2014)

Hepatitis C Virus (HCV)–Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design
por: Wrensch, Florian, et al.
Publicado: (2018)

Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV
por: Marín, María Q., et al.
Publicado: (2020)

Alcohol Consumption and Hepatitis C Virus (HCV) RNA Levels in HIV/HCV Coinfected Patients
por: Fuster, Daniel, et al.
Publicado: (2021)

Comparison of Quasispecies Diversity of HCV between Chronic Hepatitis C and Hepatocellular Carcinoma by Ultradeep Pyrosequencing
por: Park, Chang-Wook, et al.
Publicado: (2014)

NOT AN ALL OUT FAILURE: RRT IN AKI IN PATIENTS WITH COVID-19
por: GRANT-SITTOL, JANEEN, et al.
Publicado: (2021)

The performance of hepatitis C virus (HCV) antibody point‐of‐care tests on oral fluid or whole blood and dried blood spot testing for HCV serology and viral load among individuals at higher risk for HCV in South Africa
por: Prabdial‐Sing, Nishi, et al.
Publicado: (2021)

Safe, Long-term Hepatic Expression of Anti-HCV shRNA in a Nonhuman Primate Model
por: Suhy, David A, et al.
Publicado: (2012)

Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy
por: Arruda, Raissa M, et al.
Publicado: (2020)

Reversal of Immunity After Clearance of Chronic HCV Infection—All Reset?
por: Wedemeyer, Heiner, et al.
Publicado: (2020)

Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients
por: Hatu, Giorgiana, et al.
Publicado: (2014)

Evaluation of a new point-of-care oral anti-HCV test for screening of hepatitis C virus infection
por: Liu, Lili, et al.
Publicado: (2020)

Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
por: Jamalidoust, Marzieh, et al.
Publicado: (2017)

Cost-Effectiveness of All-Oral Regimens for the Treatment of Multidrug-Resistant Tuberculosis in Korea: Comparison With Conventional Injectable-Containing Regimens
por: Park, Hae-Young, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sgmsvkcqb5dpi06bva535jptg3